
Alzheimer’s drugs rejected for NHS because benefits ‘too small’ to justify cost
The National Institute for Health and Care Excellence (Nice) is standing by its earlier decision to turn down donanemab and lecanemab after considering new information submitted by manufacturers. Charities described the decision as “disappointing” and a “ …